Princeton / La Jolla / San Francisco / Portland / Dallas / Miami Beach / Chicago / Sydney / Morristown / /
Company
Only Grade 1 AE / inVentiv Health / AEs / Viralytics Limited / O.OY / /
Country
Australia / /
Currency
pence / USD / /
Event
FDA Phase / /
Facility
UCSD Moores Cancer Center / Atlantic Melanoma Center / Providence Cancer Center / Mount Sinai Comprehensive Cancer Center / Darren Shafren Huntsman Cancer Institute / Mary Crowley Cancer Research Center / University of Utah / Northern California Melanoma Center / Rush University Medical Center / /
MedicalCondition
cancers / tumor / breast cancers / All objective tumor / cancer / infectious virus / prostate cancers / vivo tumor / melanoma / IV malignant melanoma / cutaneous melanoma / complete melanoma / metastatic melanoma / /
Organization
Darren Shafren Huntsman Cancer Institute / Rush University Medical Center / Mary Crowley Cancer Research Center / University of Utah / Salt Lake City / UCSD Moores Cancer Center / Northern California Melanoma Center / Atlantic Melanoma Center / Providence Cancer Center / Comprehensive Cancer Center / /
Person
Gregory A. Daniels / Robert H.I. Andtbacka / Jose Lutzky / Karl Zhou / John J. Nemunaitis / Brendan Curti / Eric D. Whitman / Lynn E. Spitler / Roberta Karpathy / Howard Kaufman / /
Product
CVA21 / /
ProvinceOrState
Texas / New Jersey / Utah / Illinois / Florida / California / /
CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, Coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma. Robert H.I. Andtbacka, Brendan Curti, Howard